Ascentage Pharma Group Internat AAPG
Regular-session close
After hours · Nov 18, 4:00 PM ET
- YTD
- -50.41%
- 1 year
- -59.33%
- Market cap
- 1.21B
- Revenue (ttm)
- 642.64M
- Profit margin
- -228.54%
- EPS (ttm)
- -2.26
- Shares out
- 93.33M
- Forward P/E
- -19.66
- YTD return
- -50.41%
- 1-year return
- -59.33%
- 50-day average
- 15.22
- 200-day average
- 19.48
- Volume
- 1.76K
- Avg volume
- 7.42K
- Open
- 12.97
- Previous close
- 13.22
- Day's range
- 12.96 – 13.01
- 52-week range
- 12.96 – 33.09
- Beta
- 0.77
- Analysts
- Strong Buy
- Price target
- 44.50 (+242.0%)
- Earnings date
- Mar 31, 2027
5D -2.06 (-13.55%)
Key statistics
- Enterprise value
- 1.43B
- Price / sales
- 1.89
- Price / book
- 14.57
- Revenue growth
- 29.30%
- Free cash flow
- -956.54M
- Total cash
- 1.90B
- Total debt
- 2.09B
- Return on equity
- -236.63%
- Short % of float
- 0.01%
Fundamental scorecard
4 of 25 checks passed on AAPG’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 33.00
- Target (mean)
- 44.50
- Target (high)
- 55.00
- Strong buy3
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 31, 2027
Expected Mar 31, 2027. Consensus EPS estimate -0.56044.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 31, 2027 | Dec 30, 2026 | -0.30016 | — | — | — |
| Aug 18, 2026 | Jun 30, 2026 | -0.22 | -1.30 | -1.08 | -490.97% |
| Mar 24, 2026 | Dec 31, 2025 | -0.83 | -0.65 | +0.18 | +21.69% |
| Aug 20, 2025 | Jun 30, 2025 | — | -0.96391 | — | — |
| Mar 27, 2025 | Dec 31, 2024 | 0.01652 | -0.99692 | -1.01 | -6,134.62% |
| Aug 22, 2024 | Jun 30, 2024 | — | 0.3082 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 14, 2026 | Citigroup | init | — | Buy |
| Oct 13, 2026 | Citizens | init | — | Market Outperform |
| Oct 8, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 21, 2026 | BTIG | reit | Buy | Buy |
| Jun 15, 2026 | BTIG | reit | Buy | Buy |
About Ascentage Pharma Group Internat
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- ascentage.cn
News
BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target
Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib Ascentage Pharma To Present Data On Four Innovative Drug Candidates At ASH 2026, Including First Clinical Results For APG-5918
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
Ascentage Pharma Stock Could More Than Double: Analyst
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 4% – Should You Buy?
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
Your note
Sign in to keep a note on AAPG — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 0.01% | 12,228 | 159.12K | Sep 29, 2026 |
| Nisa Investment Advisors, L.L.C. | 0.00% | 5 | 65 | Sep 29, 2026 |
| Eversource Wealth Advisors, Llc | 0.00% | 24 | 312 | Sep 29, 2026 |
| Citigroup Inc. | 0.00% | 1 | 13 | Sep 29, 2026 |
| Nuveen, LLC | 0.00% | 79 | 1.03K | Sep 29, 2026 |
| Arax Advisory Partners | 0.00% | 1,230 | 16.00K | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.00% | 1,558 | 20.27K | Sep 29, 2026 |
